TN2013000393A1 - Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase - Google Patents
Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylaseInfo
- Publication number
- TN2013000393A1 TN2013000393A1 TNP2013000393A TN2013000393A TN2013000393A1 TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1 TN P2013000393 A TNP2013000393 A TN P2013000393A TN 2013000393 A TN2013000393 A TN 2013000393A TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1
- Authority
- TN
- Tunisia
- Prior art keywords
- acetyl
- coa carboxylase
- pyrazolospirocetone
- inhibitors
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Photographic Processing Devices Using Wet Methods (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention propose un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables associés; dans laquelle G représente (II) ou (III); R1, R2 et R3 sont tels que décrite ici; leurs compositions pharmaceutiques associées; et leur utilisation associée dans le traitement de maladies, états ou troubles modulés par l'inhibition d'une (d') enzyme (s) acétyl-CoA carboxylase chez un animal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478240P | 2011-04-22 | 2011-04-22 | |
PCT/IB2012/051732 WO2012143813A1 (fr) | 2011-04-22 | 2012-04-09 | Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2013000393A1 true TN2013000393A1 (fr) | 2015-01-20 |
Family
ID=46025823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2013000393A TN2013000393A1 (fr) | 2011-04-22 | 2013-09-27 | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase |
Country Status (41)
Country | Link |
---|---|
US (4) | US8802688B2 (fr) |
EP (1) | EP2699576B1 (fr) |
JP (1) | JP5657174B2 (fr) |
KR (1) | KR101567659B1 (fr) |
CN (2) | CN106117205B (fr) |
AP (1) | AP3499A (fr) |
AR (1) | AR086198A1 (fr) |
AU (1) | AU2012245996B2 (fr) |
CA (1) | CA2831380C (fr) |
CL (1) | CL2013002794A1 (fr) |
CO (1) | CO6801757A2 (fr) |
CR (1) | CR20130464A (fr) |
CU (1) | CU24164B1 (fr) |
CY (1) | CY1117122T1 (fr) |
DK (1) | DK2699576T3 (fr) |
DO (1) | DOP2013000243A (fr) |
EA (1) | EA022375B1 (fr) |
EC (1) | ECSP13013038A (fr) |
ES (1) | ES2561452T3 (fr) |
GE (1) | GEP20166474B (fr) |
GT (1) | GT201300258A (fr) |
HR (1) | HRP20151397T1 (fr) |
HU (1) | HUE028602T2 (fr) |
IL (1) | IL228949A (fr) |
MA (1) | MA35061B1 (fr) |
ME (1) | ME02312B (fr) |
MX (1) | MX348860B (fr) |
MY (1) | MY162167A (fr) |
NI (1) | NI201300111A (fr) |
NZ (1) | NZ616156A (fr) |
PE (1) | PE20141187A1 (fr) |
PL (1) | PL2699576T3 (fr) |
PT (1) | PT2699576E (fr) |
RS (1) | RS54526B1 (fr) |
SG (1) | SG194142A1 (fr) |
SI (1) | SI2699576T1 (fr) |
TN (1) | TN2013000393A1 (fr) |
TW (1) | TWI464171B (fr) |
UA (1) | UA107753C2 (fr) |
UY (1) | UY34027A (fr) |
WO (1) | WO2012143813A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20121469A1 (es) * | 2009-11-10 | 2012-11-01 | Pfizer | Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa |
CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 |
WO2014149819A1 (fr) | 2013-03-14 | 2014-09-25 | Kalyra Pharmaceuticals, Inc. | Composés analgésiques bicycliques |
US10208044B2 (en) | 2013-05-10 | 2019-02-19 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
WO2014182943A1 (fr) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
BR112015028152A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
CA2923884A1 (fr) | 2013-09-12 | 2015-03-19 | Pfizer Inc. | Utilisation d'inhibiteurs de l'acetyl-coa carboxylase pour traiter l'acne vulgaire |
US10150728B2 (en) | 2013-10-17 | 2018-12-11 | Shionogi & Co., Ltd. | Alkylene derivatives |
WO2015089170A1 (fr) | 2013-12-12 | 2015-06-18 | Kalyra Pharmaceuticals, Inc. | Composés d'alkyle bicyclique et synthèse |
JP6741343B2 (ja) * | 2014-03-07 | 2020-08-19 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | プロペラン誘導体および合成 |
CA2892342C (fr) | 2014-05-22 | 2016-11-01 | Sylvain-Paul Morency | Outil et methode de depalletisation de couche |
CA2961605C (fr) | 2014-09-17 | 2023-01-10 | Kalyra Pharmaceuticals, Inc. | Composes bicycliques |
KR20180100152A (ko) * | 2015-12-31 | 2018-09-07 | 장쑤 태슬리 디이 파마슈티컬 컴퍼니 리미티드 | 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 |
CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
CA3063729A1 (fr) | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Composes analgesiques |
CN111406056B (zh) | 2017-11-21 | 2023-02-28 | 辉瑞公司 | 选择性acc抑制剂的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐 |
CN111574530B (zh) * | 2020-04-21 | 2022-07-26 | 徐州医科大学 | 一种acc抑制剂及其医药用途 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
DE60219295T2 (de) | 2001-02-28 | 2008-01-03 | Merck & Co., Inc. | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten |
KR20040095239A (ko) | 2002-02-27 | 2004-11-12 | 화이자 프로덕츠 인코포레이티드 | Acc 억제제 |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
GEP20084421B (en) | 2004-05-12 | 2008-07-10 | Pfizer Prod Inc | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
US20050267221A1 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
CA2568056A1 (fr) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Derives de tetraazabenzo[e]azulene et analogues de ceux-ci |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
WO2007011811A1 (fr) | 2005-07-19 | 2007-01-25 | Merck & Co., Inc. | Derives de spirochromanone utilises comme inhibiteurs de carboxylase de coenzyme d'acetyle (acc) |
CA2617042A1 (fr) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Compose spiro-cyclique |
JP2009515971A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロヒダントインアリールcgrp受容体アンタゴニスト |
WO2007095603A2 (fr) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Nouveaux inhibiteurs d'acétyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique |
ES2487967T3 (es) | 2006-04-20 | 2014-08-25 | Pfizer Products Inc. | Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa |
CN101541809A (zh) | 2006-11-29 | 2009-09-23 | 辉瑞产品公司 | 螺环酮乙酰基-CoA羧化酶抑制剂 |
PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
WO2008102749A1 (fr) * | 2007-02-20 | 2008-08-28 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
US8114871B2 (en) | 2007-04-12 | 2012-02-14 | Pfizer Inc. | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
EP2297163B1 (fr) | 2008-05-28 | 2015-07-08 | Pfizer Inc. | Inhibiteurs de la pyrazolospirocétone acétyl-CoA carboxylase |
US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
WO2010002010A1 (fr) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co.,Ltd. | Nouveaux acides spirochromanone carboxyliques |
JP2011528034A (ja) | 2008-07-14 | 2011-11-10 | クロップソリューション,インコーポレイテッド | アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法 |
JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
BRPI0918841B8 (pt) | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
WO2010086820A1 (fr) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle |
WO2010103438A1 (fr) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Indazole amides substitués |
EP2406253B1 (fr) | 2009-03-11 | 2013-07-03 | Pfizer Inc. | Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase |
EP2408780A2 (fr) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3,3.1¨nonanes |
EP2427448A1 (fr) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Modulateurs du gpr119 |
CA2759843A1 (fr) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Modulateurs de gpr119 |
NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2011005611A1 (fr) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de la neuromédine u et leurs utilisations |
CA2778316A1 (fr) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | Inhibiteurs de n-2 pyrazolospirocetone acetyl-coa carboxylase |
PE20121469A1 (es) * | 2009-11-10 | 2012-11-01 | Pfizer | Inhibidores de n1- pirazoloespirocetona acetil-coa carboxilasa |
PT2621493T (pt) * | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
-
2012
- 2012-04-09 PL PL12718387T patent/PL2699576T3/pl unknown
- 2012-04-09 CU CU20130126A patent/CU24164B1/es active IP Right Grant
- 2012-04-09 AU AU2012245996A patent/AU2012245996B2/en not_active Ceased
- 2012-04-09 DK DK12718387.9T patent/DK2699576T3/en active
- 2012-04-09 EP EP12718387.9A patent/EP2699576B1/fr active Active
- 2012-04-09 CN CN201610487378.8A patent/CN106117205B/zh not_active Expired - Fee Related
- 2012-04-09 RS RS20160026A patent/RS54526B1/en unknown
- 2012-04-09 SG SG2013075148A patent/SG194142A1/en unknown
- 2012-04-09 MY MYPI2013003372A patent/MY162167A/en unknown
- 2012-04-09 ES ES12718387.9T patent/ES2561452T3/es active Active
- 2012-04-09 CA CA2831380A patent/CA2831380C/fr active Active
- 2012-04-09 HU HUE12718387A patent/HUE028602T2/hu unknown
- 2012-04-09 ME MEP-2015-214A patent/ME02312B/me unknown
- 2012-04-09 GE GEAP201213267A patent/GEP20166474B/en unknown
- 2012-04-09 MA MA36357A patent/MA35061B1/fr unknown
- 2012-04-09 JP JP2014505745A patent/JP5657174B2/ja active Active
- 2012-04-09 EA EA201391288A patent/EA022375B1/ru not_active IP Right Cessation
- 2012-04-09 AP AP2013007129A patent/AP3499A/xx active
- 2012-04-09 MX MX2013012313A patent/MX348860B/es active IP Right Grant
- 2012-04-09 NZ NZ616156A patent/NZ616156A/en not_active IP Right Cessation
- 2012-04-09 SI SI201230417T patent/SI2699576T1/sl unknown
- 2012-04-09 PT PT127183879T patent/PT2699576E/pt unknown
- 2012-04-09 KR KR1020137030875A patent/KR101567659B1/ko active IP Right Grant
- 2012-04-09 PE PE2013002387A patent/PE20141187A1/es not_active Application Discontinuation
- 2012-04-09 WO PCT/IB2012/051732 patent/WO2012143813A1/fr active Application Filing
- 2012-04-09 CN CN201280019621.3A patent/CN103492388A/zh active Pending
- 2012-04-18 TW TW101113766A patent/TWI464171B/zh not_active IP Right Cessation
- 2012-04-19 UY UY0001034027A patent/UY34027A/es not_active Application Discontinuation
- 2012-04-20 AR ARP120101364A patent/AR086198A1/es unknown
- 2012-04-21 US US13/452,839 patent/US8802688B2/en active Active
- 2012-09-04 UA UAA201311822A patent/UA107753C2/ru unknown
-
2013
- 2013-09-12 CR CR20130464A patent/CR20130464A/es unknown
- 2013-09-27 CL CL2013002794A patent/CL2013002794A1/es unknown
- 2013-09-27 TN TNP2013000393A patent/TN2013000393A1/fr unknown
- 2013-10-17 IL IL228949A patent/IL228949A/en active IP Right Grant
- 2013-10-18 GT GT201300258A patent/GT201300258A/es unknown
- 2013-10-18 NI NI201300111A patent/NI201300111A/es unknown
- 2013-10-21 DO DO2013000243A patent/DOP2013000243A/es unknown
- 2013-10-24 CO CO13252716A patent/CO6801757A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013038 patent/ECSP13013038A/es unknown
-
2014
- 2014-07-08 US US14/325,420 patent/US20140323730A1/en not_active Abandoned
-
2015
- 2015-01-09 US US14/593,370 patent/US20150112068A1/en not_active Abandoned
- 2015-08-07 US US14/820,884 patent/US20150336958A1/en not_active Abandoned
- 2015-12-21 HR HRP20151397TT patent/HRP20151397T1/hr unknown
-
2016
- 2016-01-14 CY CY20161100038T patent/CY1117122T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
MA33734B1 (fr) | N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase | |
MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
MX2013004733A (es) | Inhibidores de n1/n2-lactama acetil-coa carboxilasa. | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA38461A1 (fr) | Inhibiteurs de la voie de la kynurénine | |
MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA38138A1 (fr) | Dérivés inédits de quinolone | |
MA31873B1 (fr) | Inhibiteurs de la peptide déformylase | |
MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
MA38333A1 (fr) | Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections | |
MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine |